IQ-AI Limited Imaging Biometrics Update
April 02 2019 - 1:01AM
RNS Non-Regulatory
TIDMIQAI
IQ-AI Limited
02 April 2019
2 April 2019
IQ-AI Ltd
("IQ-AI" or the "Company")
Imaging Biometrics Update
Michael Schmainda, President of Imaging Biometrics: "This is the
first study that directly compares the single-dose (no preload),
low flip angle method to the conventional double-dose method for
creation of rCBV maps. This study is a significant step towards
creating the standard in DSC MRI for brain tumor patients, and it
has the added benefit of a reducing the amount of contrast agent
required to obtain good quality output. This marks an important
step towards our ultimate goal of providing a contrast free option
for MR imaging."
Imaging Biometrics(TM), LLC ("IB"), a 100% owned subsidiary of
IQ-AI Limited (LON:IQAI), was recently featured in an American
Journal of Neuro Radiology publication titled: "Moving Towards a
Consensus DSC-MRI Protocol: Validation of A Low Flip Angle Single
Dose Option as a Reference Standard for Brain Tumors".
The publication highlighted a study involving magnetic resonance
dynamic susceptibility contrast in magnetic resonance imaging
(DSC-MRI) for brain tumor patients. IB's software products, IB
Neuro and IB Delta Suite, were used to generate quantitative
perfusion relative cerebral blood volume ("rCBV") values with the
specific goal of determining if a single-dose of contrast agent,
combined with a low-flip angle DSC-MRI method, can provide rCBV
information comparable to the commonly accepted double-dose
method.
DSC-MRI is the most common approach used to measure brain tumor
perfusion. It provides critical information regarding tumor grade,
treatment response, and prognosis. Despite these benefits, full
adoption has been impeded due to disagreement regarding how to
collect and analyse the data.
The multi-center team, including researchers from the Medical
College of Wisconsin, The Mayo Clinic, The Barrow Neurological
Institute, and Rhode Island Hospital, revealed an interesting
performance-based option for 3T MRI scanners. While using the
well-established preload of contrast agent and applying the proven
contrast leakage correction methods of IB Neuro, the team realized
that data obtained without a preload dose of contrast and a lower
flip-angle produced rCBV maps comparable to the accepted
double-dose option. Moreover, an even better and less variable
agreement was obtained between the double-dose and no-preload
method when the rCBV data was standardised using IB Neuro's
exclusive technology. Standardisation is an automated image
intensity calibration step that renders the data to be truly
quantitative - independent of scanner, field strength, patient or
time point.
The Directors of the Company accept responsibility for the
contents of this announcement.
--ENDS--
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Fungai Ndoro
Tel: 020 7220 9797
----------------------------------------------------------
ABOUT Imaging Biometrics(TM), LLC
Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI),
develops and provides visualization and analytical solutions that
enable clinicians to better diagnose and treat diseases with
greater confidence. Through close collaboration with top
researchers and clinicians, sophisticated advancements are
translated into platform-independent software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualization
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGUMCCUPBGAG
(END) Dow Jones Newswires
April 02, 2019 02:01 ET (06:01 GMT)
Flying Brand (LSE:FBDU)
Historical Stock Chart
From Dec 2024 to Jan 2025
Flying Brand (LSE:FBDU)
Historical Stock Chart
From Jan 2024 to Jan 2025